Zolpidem is one of the most frequently used hypnotics worldwide, but associations with serious adverse effects such as motor vehicle collisions have been reported.
The objective of this study was to evaluate the association of fatal motor vehicle collisions with a prescription for zolpidem, considering the context of the motor vehicle collisions.
We conducted a case-crossover study, where each case served as its own control, by linking data about fatal motor vehicle collisions from the Korean Road Traffic Authority between 2010 and 2014 with national health insurance data. The case period was defined as 1 day before the fatal motor vehicle collisions, and was matched to four control periods at 90-day intervals. Conditional logistic regression was performed to calculate the odds ratio for fatal motor vehicle collisions associated with zolpidem exposure, and odds ratios were adjusted for time-varying exposure to confounding medications. A stratified analysis was performed by age group (younger than 65 years or not), the Charlson Comorbidity Index, and whether patients were new zolpidem users.
Among the 714 subjects, the adjusted odds ratio for a fatal motor vehicle collision associated with a prescription for zolpidem the previous day was 1.48 (95% confidence interval 1.06–2.07). After stratification, a significantly increased risk was observed in subjects with a high Charlson Comorbidity Index (odds ratio 1.81; 95% confidence interval 1.16–2.84), the younger age group (odds ratio: 1.62; 95% confidence interval 1.03–2.56), and new zolpidem users (odds ratio 2.37; 95% confidence interval 1.40–4.00).
A prescription for zolpidem on the previous day was significantly related to an increased risk of fatal motor vehicle collisions in this population-based case-crossover study.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Med. 2014;15(2):173–9.
Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, et al. Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 National Psychiatric Morbidity Surveys. Sleep. 2012;35(3):377–84.
Chung S, Park B, Yi K, Lee J. Pattern of hypnotic drug prescription in South Korea: health insurance review and assessment service: national patients sample. Sleep Med Res. 2013;4(2):51–5.
Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol. 2013;9(2):163–71.
Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.
Berthelon C, Bocca ML, Denise P, Pottier A. Do zopiclone, zolpidem and flunitrazepam have residual effects on simulated task of collision anticipation? J Psychopharmacol. 2003;17(3):324–31.
Ganzoni E, Santoni JP, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res. 1995;23(1):61–73.
Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297–328.
Gibson JE, Hubbard RB, Smith CJ, Tata LJ, Britton JR, Fogarty AW. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol. 2009;169(6):761–8.
Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Morland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008;9(8):818–22.
Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595–601.
Yang YH, Lai JN, Lee CH, Wang JD, Chen PC. Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol. 2011;21(1):37–43.
Jung SY, Hwang B, Yang BR, Kim YJ, Lee J. Risk of motor vehicle collisions associated with medical conditions and medications: rationale and study protocol. Inj Prev. 2017;23(5):356.
Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799–800.
Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.
Food Korea, Administration Drug. Appropriate prescribing guideline for the elderly. Seoul: Korea Food and Drug Administration; 2009.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
Bannay A, Chaignot C, Blotiere PO, Basson M, Weill A, Ricordeau P, et al. The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality. Med Care. 2016;54(2):188–94.
Huang YQ, Gou R, Diao YS, Yin QH, Fan WX, Liang YP, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B. 2014;15(1):58–66.
Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev. 1994;26(2):243–7.
Cheng HT, Lin FJ, Erickson SR, Hong JL, Wu CH. The association between the use of zolpidem and the risk of Alzheimer’s disease among older people. J Am Geriatr Soc. 2017;65(11):2488–95.
Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ. 1980;32:5–338.
Firth D. Bias reduction of maximum-likelihood-estimates. Biometrika. 1993;80(1):27–38.
Sun JX, Sinha S, Wang SJ, Maiti T. Bias reduction in conditional logistic regression. Stat Med. 2011;30(4):348–55.
Booth JN, Behring M, Cantor RS, Colantonio LD, Davidson S, Donnelly JP, et al. Zolpidem use and motor vehicle collisions in older drivers. Sleep Med. 2016;20:98–102.
Meskali M, Berthelon C, Marie S, Denise P, Bocca ML. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. Psychopharmacology (Berl). 2009;207(3):461–7.
Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576–83.
Vermeeren A, Ohanlon JF, Declerck AC, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep-deprivation and placebo. Acta Therap. 1995;21(1):47–64.
Verster JC, Volkerts ER, Olivier B, Johnson W, Liddicoat L. Zolpidem and traffic safety: the importance of treatment compliance. Curr Drug Saf. 2007;2(3):220–6.
Wong CK, Marshall NS, Grunstein RR, Ho SS, Fois RA, Hibbs DE, et al. Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. J Clin Sleep Med. 2017;13(2):223–34.
Paulke A, Wunder C, Toennes SW. Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour. Int J Legal Med. 2015;129(1):85–8.
Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009;5(5):471–6.
Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.
Mortaz Hejri S, Faizi M, Babaeian M. Zolpidem-induced suicide attempt: a case report. DARU. 2013;21(1):77.
Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based case-control study. Mayo Clin Proc. 2016;91(3):308–15.
Nevriana A, Moller J, Laflamme L, Monarrez-Espino J. New, occasional, and frequent use of zolpidem or zopiclone (alone and in combination) and the risk of injurious road traffic crashes in older adult drivers: a population-based case-control and case-crossover study. CNS Drugs. 2017;31(8):711–22.
Booth JN 3rd, Behring M, Cantor RS, Colantonio LD, Davidson S, Donnelly JP, et al. Zolpidem use and motor vehicle collisions in older drivers. Sleep Med. 2016;20:98–102.
Fong CK, Keay L, Coxon K, Clarke E, Brown J. Seat belt use and fit among drivers aged 75 years and older in their own vehicles. Traffic Inj Prev. 2016;17(2):142–50.
Gwyther H, Holland C. The effect of age, gender and attitudes on self-regulation in driving. Accid Anal Prev. 2012;45:19–28.
Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010;19(12):1248–55.
Vlase L, Popa A, Neag M, Muntean D, Achim M, Leucuta SE. Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol. 2012;39(1):9–12.
Coleman DE, Ota K. Hallucinations with zolpidem and fluoxetine in an impaired driver. J Forensic Sci. 2004;49(2):392–3.
This research was funded as part of the ‘Technology Development for Behavior Improvement and Violation Control of High Risk Drivers’ project carried out by the Ministry of Land, Infrastructure and Transport in Korea [Grant no. 14TLRP-B085437-01]. The funding body did not play a role in the study design, writing of the manuscript, or in the decision to submit the manuscript for publication.
Conflict of interest
Bo Ram Yang, Ye-Jee Kim, Mi-Sook Kim, Sun-Young Jung, Nam-Kyong Choi, Byungkwan Hwang, Byung-Joo Park, and Joongyub Lee have no conflicts of interest directly relevant to the content of this article.
About this article
Cite this article
Yang, B.R., Kim, Y., Kim, M. et al. Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea. CNS Drugs 32, 593–600 (2018). https://doi.org/10.1007/s40263-018-0520-x